Cardiovascular Risk Assessment Using the Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score Model After Continuing or Switching to a Doravirine-Based HIV Treatment Regimen

By afschroeder • October 14, 2025

Hsue PY, Behrens GMN, Xu ZJ, Zhao Y, Cmar J, Lahoulou R, Campo RE, Plank RM. Cardiovascular Risk Assessment Using the Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score Model After Continuing or Switching to a Doravirine-Based HIV Treatment Regimen. J Acquir Immune Defic Syndr. 2025 Oct 13. doi: 10.1097/QAI.0000000000003778. Epub ahead of print. PMID: 41081774.

Tags: atherosclerotic cardiovascular disease, Cardiology/Epi, cardiometabolic, doravirine, HIV-1, nonnucleoside reverse transcriptase inhibitor, Publications, safety, switch

Related Posts

Dosimetry Analysis of 177Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial

Ells Z, Meyer C, Kimura K, Wilhalme H, Cao M, Ludwig VB, Unterrainer LM, Sennung D, Nabong R, Felix C, Valle LF, Daley A, Czernin[...]

Blood Pressure Genetic Risk and Incident Hypertension at 2 to 7 Years Post Partum

Hemeryck J, De Moor N, Ezzat D, Khan RR, Vandergrift N, Levine LD, Rouse C, Theilen LH, Bairey Merz CN, Yee LM, Chung J, Bello[...]

Time to Quadruple Therapy After Initial Diagnosis of Heart Failure With Reduced Ejection Fraction

Jacobs JA, Greene T, Vanneman ME, Kean J, Carter SJ, Shah KS, Pandey A, Derington CG, Zheutlin AR, Fang J, Stehlik J, Fonarow GC, Bress[...]